

## Supplementary Table 2. Clinical outcomes during initial 6 cycles of cisplatin-doublet chemotherapy

Variable	Gemcitabine cisplatin	Capecitabine cisplatin	
Best response			
Partial response	15 (15.6)	21 (21.9)	
Stable disease	8 (8.3)	34 (35.4)	
Overall response rate	36 (37	36 (37.5)	
Disease control rate	78 (8:	78 (81.3)	
Survival outcome			
Median PFS during initial 6 cycles	5.13 (4.51–5.74)	4.23 (3.41–5.05)	

Values are presented as number (%) or 95% confidence interval.

PFS, progression-free survival.